ArticleNature communications2023
Identification of SARS-CoV-2 M
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- A Review of SERS-Based Bacterial Detection from Nanomaterials to Integrated Clinical Platforms.Biosensors · 2026Review
- Peptidomimetic α,β-Unsaturated Ethyl Esters Are Irreversible Inactivators of Human Cathepsin L and Are Potent Inhibitors of SARS-CoV-2 in Cellular Models of COVID-19.Journal of medicinal chemistry · 2026Article
- A Streamlined High Performance Liquid Chromatography with Tandem Mass Spectrometry Based Workflow for Rapid Screening of Cellular Accumulation of Small Molecules.ChemMedChem · 2026Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.Journal of virology · 2025Article
- SARS-CoV‑2 Papain-Like Protease Inhibitors Based on Naphthalen-1-ylethanamine and Halogenated Benzene Moieties.ACS omega · 2025Article
- SARS-CoV‑2 Main Protease Inhibitors Containing 5‑Substituted Benzothiazole-2-carbonyl Moieties at the P1' Site and Their Derivatives.ACS omega · 2025Article
- Unlocking the potential of the thioamide group in drug design and development.Future medicinal chemistry · 2025Article
- An orally available P1'-5-fluorinated MPNAS nexus · 2025Article
- Thioamides in medicinal chemistry and as small molecule therapeutic agents.European journal of medicinal chemistry · 2024Review
- Structural and virologic mechanism of the emergence of resistance to MProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Review
- Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion.RSC chemical biology · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.Biomolecules · 2023Review
- Contrasting mechanistic susceptibilities of hematopoietic and endothelial stem-progenitor cells in respective pathogeneses of HIV-1 and SARS-CoV-2 infections.Frontiers in cell and developmental biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 11 institutions in 2 countries.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0002-9404-3532
Kohei TsujiDepartment of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0003-4773-8793
Hironori HayashiDepartment of Infectious Diseases, International Research Institute of Disaster Science, Tohoku University, Miyagi, Japan.ORCID 0000-0002-5892-0040
Haydar BulutExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0003-0262-6296
Maki KisoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Masaki ImaiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Hiromi Ogata-AokiExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-9290-911X
Takahiro IshiiDepartment of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0003-1664-6191
Takuya KobayakawaDepartment of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0001-9786-2608
Kenta NakanoDepartment of Laboratory Animal Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Nobutoki TakamuneDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-7173-240X
Naoki KishimotoDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-9401-8118
Shin-Ichiro HattoriDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0002-5637-3397
Debananda DasExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0001-9943-5888
Yukari UemuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Yosuke ShimizuCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-9255-3395
Manabu AokiExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0001-7089-831X
Kazuya HasegawaStructural Biology Division, Japan Synchrotron Radiation Research Institute, Hyogo, Japan.ORCID 0000-0003-0331-1624
Satoshi SuzukiDepartment of Infectious Diseases, Tohoku University Graduate School of Medicine, Miyagi, Japan.ORCID 0000-0002-5122-0180
Akie NishiyamaDepartment of Infectious Diseases, Tohoku University Graduate School of Medicine, Miyagi, Japan.ORCID 0000-0002-1645-4248
Junji SaruwatariDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-6266-1347
Yukiko ShimizuDepartment of Laboratory Animal Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0003-2120-3993
Yoshikazu SukenagaDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Yuki TakamatsuDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0001-7967-1576
Kiyoto TsuchiyaAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-8233-6653
Kenji MaedaDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Kazuhisa YoshimuraTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Shun IidaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0003-2258-9031
Seiya OzonoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-3820-9542
Tadashi OkamuraDepartment of Laboratory Animal Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0001-8457-1561
Shogo MisumiDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-9465-4720
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0001-5061-8296
Hirokazu TamamuraDepartment of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0003-2788-2579
Hiroaki MitsuyaDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan. hmitsuya@hosp.ncgm.go.jp.ORCID 0000-0001-9274-3853
National Center for Global Health and Medicine · JPNational Cancer Institute · USTokyo Medical and Dental University · JPKumamoto Health Science University · JPNational Institute of Infectious Diseases · JPTohoku University · JPTokyo University of Science · JPJapan Synchrotron Radiation Research Institute · JPKumamoto University · JPTokyo Metropolitan Institute of Public Health · JPUniversity of Wisconsin–Madison · US
Funding
Development of therapeutics for SARS-CoV-2 infectionZIABC012018 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2020 to 2025
$2.6MAbstract
COVID-19 caused by SARS-CoV-2 has continually been serious threat to public health worldwide. While a few anti-SARS-CoV-2 therapeutics are currently available, their antiviral potency is not sufficient. Here, we identify two orally available 4-fluoro-benzothiazole-containing small molecules, TKB245 and TKB248, which specifically inhibit the enzymatic activity of main protease (M
Indexed as
Antiviral AgentsCoronavirus 3C ProteasesCOVID-19Protease InhibitorsSARS-CoV-2AnimalsBenzothiazolesHumansIndazolesMiceMolecular Docking SimulationTriazinesTriazolesViral Nonstructural Proteins3C-like proteinase, SARS-CoV-2Antiviral AgentsBenzothiazolesCoronavirus 3C ProteasesensitrelvirIndazolesProtease InhibitorsTriazinesTriazolesViral Nonstructural Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.